Platform Trial of Novel Regimens Versus Standard of Care (SoC) in Participants With Non-small Cell Lung Cancer (NSCLC)

Active:	Yes
Cancer Type:	Lung Cancer	NCT ID:	NCT03739710
Trial Phases:	Phase II	Protocol IDs:	205801 (primary) NCI-2018-03390
Eligibility:	18 Years and older, Male and Female	Study Type:	Treatment
Study Sponsor:	GlaxoSmithKline
NCI Full Details:	http://clinicaltrials.gov/show/NCT03739710

Summary

This study will compare the clinical activity of novel regimens (in combination or as
single agents) to SoC in participants with relapsed/refractory advanced NSCLC. The study
will be conducted in two parts. Part 1 is an open-label, optional, non-randomized part
based on safety and pharmacokinetics/pharmacodynamics (PK/PD) evaluation intended to
generate additional data to qualify novel regimens for the randomized study. Part 2 is a
randomized, Phase II open-label part comparing the efficacy and safety of these novel
regimens with SoC. Drug name mentioned as GSK4428859A (belrestotug) and EOS884448 are
interchangeable for the same compound and will be referred to as
GSK4428859A/EOS884448/belrestotug.

Treatment Sites in Georgia

Winship Cancer Institute of Emory University
1365 Clifton Road NE
Building C
Atlanta, GA 30322
winshipcancer.emory.edu

**Clinical trials are research studies that involve people. These studies test new ways to prevent, detect, diagnose, or treat diseases. People who take part in cancer clinical trials have an opportunity to contribute to scientists’ knowledge about cancer and to help in the development of improved cancer treatments. They also receive state-of-the-art care from cancer experts... Click here to learn more about clinical trials.